Oncogenes y Dianas Efectoras
PANCCUN
Translational Genomics Research Institute
Phoenix, Estados UnidosPublicaciones en colaboración con investigadores/as de Translational Genomics Research Institute (2)
2021
-
Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial
Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027
2020
-
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Nature Medicine, Vol. 26, Núm. 6, pp. 878-885